Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LMB062
MIFTS: 55

Limb Ischemia

Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Limb Ischemia

About this section

MalaCards integrated aliases for Limb Ischemia:

Name: Limb Ischemia 12 15 37 70

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050852
UMLS 70 C2945695
Sources

Summaries for Limb Ischemia

About this section
Disease Ontology : 12 An ischemia that is characterized by low blood supply to tissues in the limb due to interruption in the arterial blood supply.

MalaCards based summary : Limb Ischemia is related to peripheral vascular disease and ischemia. An important gene associated with Limb Ischemia is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone, and related phenotypes are cardiovascular system and cellular

Sources

Related Diseases for Limb Ischemia

About this section

Diseases related to Limb Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 644)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 31.6 VWF VEGFA SELE IL6 F2 CCL2
2 ischemia 31.5 VEGFA TEK SELE NOS3 MIR21 KDR
3 compartment syndrome 31.4 TNF IL6 F2
4 arteriosclerosis obliterans 31.4 MIR21 IL6 HGF
5 end stage renal disease 31.2 VEGFA TNF NOS3 IL6 CCL2 ACE
6 cardiogenic shock 31.1 TNF IL6
7 congestive heart failure 31.1 VEGFA TNF NOS3 IL6 ACE
8 endocarditis 30.9 TNF IL6 F2
9 arteries, anomalies of 30.9 VEGFA TNF NOS3 MIR21 IL6 CCL2
10 aortic aneurysm, familial abdominal, 1 30.9 TNF NOS3 IL6 CCL2 ACE
11 osteomyelitis 30.9 TNF IL6 CCL2
12 severe acute respiratory syndrome 30.9 TNF IL6 CCL2 ACE
13 peripheral artery disease 30.9 VWF VEGFA TNF NOS3 IL6 HIF1A
14 vasculitis 30.9 VWF TNF SELE IL6 CCL2
15 antiphospholipid syndrome 30.8 VWF TNF SELE F2
16 lipid metabolism disorder 30.8 SELE IL6 CCL2 ACE
17 intermittent claudication 30.7 VWF VEGFA TEK PGF IL6 F2
18 polyarteritis nodosa 30.7 SELE IL6 FGF2
19 systemic scleroderma 30.7 TNF SELE IL6 ACE
20 disseminated intravascular coagulation 30.6 VWF TNF IL6 F2
21 proteasome-associated autoinflammatory syndrome 1 30.6 TNF SELE IL6 CCL2
22 cerebrovascular disease 30.6 VWF TNF SELE MIR21 IL6 F2
23 chronic ulcer of skin 30.6 VEGFA TNF IL6 FGF2
24 covid-19 30.6 VWF IL6 CCL2 ACE
25 pneumonia 30.6 TNF IL6 CCL2 ACE
26 respiratory failure 30.5 VEGFA TNF IL6 F2 CCL2 ANGPT2
27 cellulitis 30.5 TNF IL6 F2
28 homocysteinemia 30.5 VWF NOS3 F2 CCL2
29 vascular disease 30.4 VWF VEGFA TNF SELE NOS3 MIR21
30 pulmonary edema 30.4 TNF TEK NOS3 HIF1A F2 ACE
31 angina pectoris 30.4 NOS3 IL6 ACE
32 hyperglycemia 30.4 SELE NOS3 IL6 HIF1A
33 arteriosclerosis 30.4 SELE NOS3 MIR21 IL6 HIF1A HGF
34 atherosclerosis susceptibility 30.4 VWF VEGFA TNF SELE NOS3 IL6
35 thrombocytosis 30.4 VWF IL6 F2
36 soft tissue sarcoma 30.4 VEGFA TNF HIF1A
37 kidney disease 30.3 VEGFA TNF NOS3 MIR21 IL6 HGF
38 purpura 30.3 VWF TNF IL6 F2 ACE
39 essential thrombocythemia 30.3 VWF VEGFA TNF IL6 FGF2 F2
40 myocarditis 30.3 TNF IL6 CCL2 ACE
41 acute myocardial infarction 30.3 VWF SELE MIR21 IL6 ACE
42 uremia 30.3 VWF TNF IL6 ACE
43 peripartum cardiomyopathy 30.3 VEGFA PGF MIR21 ACE
44 infective endocarditis 30.3 TNF IL6 F2
45 sarcoma 30.2 VEGFA KDR IL6 HIF1A FGF2 ANGPT2
46 localized scleroderma 30.2 TNF SELE IL6
47 decubitus ulcer 30.2 VEGFA TNF IL6 FGF2
48 adult respiratory distress syndrome 30.2 TNF SELE IL6 F2 ANGPT2 ACE
49 plague 30.2 TNF SELE IL6
50 exanthem 30.2 VEGFA TNF IL6 F2 ACE

Graphical network of the top 20 diseases related to Limb Ischemia:



Diseases related to Limb Ischemia
Sources

Symptoms & Phenotypes for Limb Ischemia

About this section

MGI Mouse Phenotypes related to Limb Ischemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 ACE ANGPT2 CXCL12 F2 FGF2 HGF
2 cellular MP:0005384 10.35 ANGPT2 CXCL12 F2 FGF2 HGF HIF1A
3 hematopoietic system MP:0005397 10.34 ACE ANGPT2 CXCL12 FGF2 HGF HIF1A
4 homeostasis/metabolism MP:0005376 10.32 ACE ANGPT2 F2 FGF2 HIF1A IL6
5 immune system MP:0005387 10.3 ACE ANGPT2 CCL2 CXCL12 F2 HIF1A
6 mortality/aging MP:0010768 10.24 ACE ANGPT2 CXCL12 F2 FGF2 HGF
7 embryo MP:0005380 10.16 ACE F2 HGF HIF1A KDR PGF
8 digestive/alimentary MP:0005381 10.13 ANGPT2 F2 HIF1A IL6 NOS3 TNF
9 integument MP:0010771 10.13 ANGPT2 F2 HIF1A IL6 KDR PGF
10 liver/biliary system MP:0005370 10.1 ACE CXCL12 HGF HIF1A IL6 KDR
11 muscle MP:0005369 10.02 CXCL12 F2 FGF2 HIF1A IL6 KDR
12 nervous system MP:0003631 9.97 ACE CXCL12 F2 FGF2 HGF HIF1A
13 neoplasm MP:0002006 9.8 ACE FGF2 HIF1A IL6 PGF TNF
14 respiratory system MP:0005388 9.65 ANGPT2 F2 HIF1A IL6 KDR NOS3
15 vision/eye MP:0005391 9.4 ACE ANGPT2 FGF2 HIF1A IL6 KDR
Sources

Drugs & Therapeutics for Limb Ischemia

About this section

Drugs for Limb Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Evolocumab Approved Phase 4 1256937-27-5
4
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
5
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
6 Platelet Aggregation Inhibitors Phase 4
7 Pharmaceutical Solutions Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Cyclooxygenase Inhibitors Phase 4
10 Antirheumatic Agents Phase 4
11 Antipyretics Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Respiratory System Agents Phase 4
15 Protective Agents Phase 4
16 Neuroprotective Agents Phase 4
17 Phosphodiesterase 3 Inhibitors Phase 4
18 Bronchodilator Agents Phase 4
19 Phosphodiesterase Inhibitors Phase 4
20 Lipid Regulating Agents Phase 4
21 Anticholesteremic Agents Phase 4
22 Antimetabolites Phase 4
23 Hypolipidemic Agents Phase 4
24 Vasodilator Agents Phase 4
25 Analgesics Phase 4
26 Psychotropic Drugs Phase 4
27 Anticonvulsants Phase 4
28 calcium channel blockers Phase 4
29 Anti-Anxiety Agents Phase 4
30 Calcium, Dietary Phase 4
31 Hormones Phase 4
32
Calcium Nutraceutical Phase 4 7440-70-2 271
33
Caffeine Approved Phase 3 58-08-2 2519
34
Procaine Approved, Investigational, Vet_approved Phase 3 59-46-1 4914
35
Iron Approved Phase 3 7439-89-6 23925 29936
36
Pentetic acid Approved Phase 3 67-43-6
37
Edetic Acid Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
38
Apixaban Approved Phase 3 503612-47-3 10182969
39
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
40
Clopidogrel Approved Phase 2, Phase 3 113665-84-2, 120202-66-6 60606
41
Treprostinil Approved, Investigational Phase 3 81846-19-7 54786 6918140
42
Ticagrelor Approved Phase 2, Phase 3 274693-27-5 9871419
43
Pantothenic acid Approved, Nutraceutical, Vet_approved Phase 3 79-83-4 6613
44
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 70-16-6, 59-43-8 1130
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
46 Anesthetics Phase 3
47 Calamus Phase 3
48 Anticoagulants Phase 3
49 Serine Proteinase Inhibitors Phase 3
50 Antithrombin III Phase 3

Interventional clinical trials:

(show top 50) (show all 311)
# Name Status NCT ID Phase Drugs
1 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
2 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
3 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
4 CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5). Completed NCT00459888 Phase 4
5 International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease Completed NCT02369809 Phase 4 Neovasculgen®
6 Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study Completed NCT01558505 Phase 4
7 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
8 Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) Completed NCT00596752 Phase 4 Alprostadil
9 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Completed NCT02563535 Phase 4
10 Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) Recruiting NCT02829151 Phase 4 Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
11 Effect of Evolocumab in Patients With Critical Limb Ischemia Recruiting NCT04306471 Phase 4 Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
12 Efficacy of Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Patients With Critical Limb Ischemia. Not yet recruiting NCT04312555 Phase 4 Alprostadil
13 Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study Terminated NCT00403780 Phase 4 pregabalin;placebo
14 Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Terminated NCT00504088 Phase 4
15 Proteomics and Stem Cell Therapy as a New Vascularization Strategy Withdrawn NCT02408991 Phase 4 Neupogen
16 The Impact of Repeated Bilateral Limb Remote Ischemic Conditioning on Patients With Chronic Cerebral Ischemia: Establishment of Optimized Algorithm on the Basis of Feasibility, Safety and Efficacy Unknown status NCT03105141 Phase 2, Phase 3
17 Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG) Unknown status NCT01818310 Phase 2, Phase 3
18 Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb Unknown status NCT01211925 Phase 2, Phase 3 Aspirin
19 Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients Unknown status NCT02538978 Phase 3
20 An Efficacy and Safety Study to Evaluate Ranger Drug-eluting Balloon for Below the Knee Angioplasty in Patients With Critical Limb Ischemia Unknown status NCT02856230 Phase 2, Phase 3
21 Study of Parameters of Infracyanine Angiography as Diagnostic Tool of Critical Limb Ischemia Unknown status NCT02820467 Phase 3
22 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients Unknown status NCT00539266 Phase 2, Phase 3
23 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization Completed NCT01483898 Phase 3
24 Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells Completed NCT01833585 Phase 3
25 Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease Completed NCT01245335 Phase 3
26 Monocentric Randomized Study for the Therapy of Critic Limb Ischemia With Bone Marrow- or Peripheral Blood-derived Stem Cells Completed NCT02454231 Phase 2, Phase 3
27 Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients: A Randomized Controlled Trial Completed NCT01328912 Phase 3
28 Clinical and Genomic Responses to Open Heart Surgery: A Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning Completed NCT00650507 Phase 3
29 A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions Completed NCT00566657 Phase 3
30 Cell Therapy in Critical Limb Ischemia Completed NCT00904501 Phase 3
31 Paclitaxel Eluting Stent in Long Superficial Femoral Artery Obstruction: a Prospective, Randomized Comparison With Bypass Surgery Using PTFE Graft in a Finnish Multicenter Study Recruiting NCT01450722 Phase 3
32 Trial to Assess Chelation Therapy in Critical Limb Ischemia Recruiting NCT03982693 Phase 3 Edetate Disodium
33 Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb Recruiting NCT04229264 Phase 3 Apixaban;ASA;Clopidogrel 75mg
34 Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI) Recruiting NCT03423732 Phase 2, Phase 3 CardioCell;Placebos
35 The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial Recruiting NCT03174522 Phase 3 REX-001;Placebo
36 The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Rest Pain in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 4 and Diabetes Mellitus (DM): a Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial Recruiting NCT03111238 Phase 3 REX-001;Placebo
37 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5） Recruiting NCT04274049 Phase 3
38 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4) Recruiting NCT04275323 Phase 3
39 A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia Active, not recruiting NCT03551496 Phase 3
40 Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization Active, not recruiting NCT03006770 Phase 3
41 Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia Active, not recruiting NCT00471289 Phase 2, Phase 3
42 A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures Terminated NCT00060996 Phase 3 Remodulin® (treprostinil sodium) Injection
43 A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia Terminated NCT02144610 Phase 3
44 Remote Ischaemic Preconditioning for Heart Surgery Terminated NCT01067703 Phase 3
45 A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft Terminated NCT00067041 Phase 2, Phase 3 Remodulin (treprostinil sodium) Injection
46 Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia Terminated NCT02230527 Phase 2, Phase 3 Ticagrelor;Clopidogrel
47 Low Dose Urokinase Therapy in Patients With Diabetic Foot Syndrome and Critical Limb Ischemia Versus Conventional Standard Therapy Terminated NCT00823225 Phase 3 Urokinase
48 Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase Terminated NCT01638585 Phase 3 urokinase
49 A Physician Initiated Prospective Multicenter Study on Excimer Laser Recanalisation in the Treatment of Long Infrapopliteal Lesions in Patients With Critical Limb Ischemia Terminated NCT00718991 Phase 2, Phase 3
50 Single Blind Randomized Controlled Crossover Trial of the Effects of Remote Preconditioning on the Tissue Metabolism During Exercise and Ischemia Unknown status NCT00791206 Phase 2

Search NIH Clinical Center for Limb Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Limb Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Limb Ischemia:
ACP-01, autologous angiogenic precursor cells for critical limb ischemia
ACT34-CLI, bone marrow-derived cells for critical limb ischemia
ACY001, bone marrow-derived hematopoietic stem cells for treatment of critical limb ischemia
ALD-301, bone marrow-derived cells for critical limb ischemia
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
Angiocell, bone marrow-derived stem cells for treatment of critical limb ischemia
Autologous CD133+ cells for treatment of critical limb ischemia
Autologous endothelial progenitor cells for the treatment of critical limb ischemia
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
BMAC, autologous bone marrow aspirate concentrate for critical limb ischemia
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Bone marrow-derived mononuclear cells for critical limb ischemia
Bone marrow-derived mononuclear cells for peripheral vascular disease
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Bone marrow-derived stem cells for treatment of critical limb ischemia and diabetic foot ulcer
Bone marrow-derived stem cells for treatment of diabetic foot ulcers
Enriched bone marrow-derived progenitor cells for ischemic diseases
ERCs, endometrial regenerative cells for critical limb ischemia
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Ixmyelocel-T, mesenchymal stem cells and myocytes for critical limb ischemia
Mesendo, stem cell combination for treatment of limb ischemia
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
PDA002, Placenta-derived cells for vascular disease
Peripheral blood-derived hematopoietic stem cells for leg gangrene
PLX-PAD, placental-derived mesenchymal-like stromal cells for peripheral artery disease
ReN009, human neural stem cells for peripheral arterial disease
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of peripheral vascular diseases
StempeucelCLI, mesenchymal stem cells for vascular diseases
Umbilical cord blood stem cells for treatment of critical limb ischemia
Embryonic/Adult Cultured Cells Related to Limb Ischemia:
Angiogenic cell precursors
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 22163120 23192920 9020076
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Bone marrow-derived mesenchymal stem cells (family)
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Bone marrow-derived mononuclear cells (family) PMIDs: 17394441 23586040 21216483
Peripheral blood-derived endothelial progenitor cells (family)
Peripheral blood-derived endothelial cells PMIDs: 18388019 19448678
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 15995108 18351022 19896796 19500466 22019148
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells
Tissue repair cells PMIDs: 17394441 23586040
Bone marrow-derived mesenchymal stem cells PMIDs: 21216483
Bone marrow-derived progenitor cells
Endometrial regenerative cells PMIDs: 18005405 18713449 19232091
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mesenchymal stem cells and monocytes (Ixmyelocel-T) PMIDs: 22453769 22776246 21684715
Bone marrow-derived mononuclear cells PMIDs: 21586448
Bone marrow-derived mesenchymal stem cells PMIDs: 21586448
MultiGeneAngio, transduced vein-derived endothelial cells
Genetically modified vein-derived endothelial cells
MultiGeneAngio, transduced vein-derived smooth muscle cells
Genetically modified vein-derived smooth muscle
Placenta-derived cells
Peripheral blood-derived hematopoietic stem cells
Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19526389 19478280
Neural stem cell line (CTX0E03) PMIDs: 23067568
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 23307180 18720444 22731756
Umbilical cord blood-derived hematopoietic stem cells (family)
Sources

Genetic Tests for Limb Ischemia

About this section
Sources

Anatomical Context for Limb Ischemia

About this section

MalaCards organs/tissues related to Limb Ischemia:

40
Bone Marrow, Endothelial, Bone, Skeletal Muscle, Heart, Placenta, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Limb Ischemia:
# Tissue Anatomical CompartmentCell Relevance
1 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
2 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
3 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate
Sources

Publications for Limb Ischemia

About this section

Articles related to Limb Ischemia:

(show top 50) (show all 7788)
# Title Authors PMID Year
1
Antithrombotic Treatment for Peripheral Arterial Occlusive Disease. 61
33734081 2021
2
Medium-term outcomes of multi-disciplinary surgical management of non-ischemic diabetic heel ulcers. 61
33717969 2021
3
Surgical OFF-LOADING of the diabetic foot. 61
33717955 2021
4
Stem cells for treatment of cardiovascular diseases: An umbrella review of randomized controlled trials. 61
33434684 2021
5
Estrogen-related receptor α is involved in angiogenesis and skeletal muscle revascularization in hindlimb ischemia. 61
33788962 2021
6
Neutrophil-lymphocyte ratio as a link between complex pedal ulcers and poor clinical results after infrainguinal surgical revascularization. 61
33496158 2021
7
Ultrasound-Mediated Microbubble Cavitation Transiently Reverses Acute Hindlimb Tissue Ischemia through Augmentation of Microcirculation Perfusion via the eNOS/NO Pathway. 61
33487472 2021
8
Outcomes of Drug-Coated Balloon Angioplasty for Isolated Chronic Occlusion of the Popliteal Artery: A Retrospective Single-Institution Study. 61
33531180 2021
9
Safety of vascular interventions performed in an office-based laboratory in patients with low/moderate procedural risk. 61
33065244 2021
10
Reduced intracellular chloride concentration impairs angiogenesis by inhibiting oxidative stress-mediated VEGFR2 activation. 61
32694758 2021
11
The association between preoperative length of stay and surgical site infection after lower extremity bypass for chronic limb-threatening ischemia. 61
32889070 2021
12
Long-term clinical outcomes and cause of death after endovascular treatment for femoropopliteal artery lesions. 61
33229235 2021
13
Evolution of Major Amputation Risk in Patients Hospitalized in France for Critical Limb Ischemia: The COPART Registry. 61
33267644 2021
14
2D-Perfusion Angiography Using Carbon Dioxide (CO2): A Feasible Tool to Monitor Immediate Treatment Response to Endovascular Therapy of Peripheral Arterial Disease? 61
33330951 2021
15
Nerve growth factor in muscle afferent neurons of peripheral artery disease and autonomic function. 61
33063730 2021
16
A systematic review and meta-analysis of gender differences in long-term mortality and cardiovascular events in peripheral artery disease. 61
33161072 2021
17
COVID-19 and Its Implications for Thrombosis and Anticoagulation. 61
33548929 2021
18
Early Identification of Argatroban Resistance and the Consideration of Factor VIII. 61
31694454 2021
19
One-year limb outcome and mortality in patients undergoing revascularization therapy for acute limb ischemia: short-term results of the Edo registry. 61
32212046 2021
20
Hirudotherapy for neonatal limb ischemia during ECMO support: A word of caution. 61
33811665 2021
21
Acute limb ischemia in a patient with Covid-19 pneumonia: a case report. 61
33797021 2021
22
Effects of upper limb ischemia-reperfusion on regional oxidative stress during aortic surgery with moderate hypothermia. 61
33567138 2021
23
Risk prediction model for early outcomes of revascularization for chronic limb-threatening ischaemia. 61
33693591 2021
24
Sex Differences of Clinical Presentation and Outcomes in Propensity-Matched Patients with Acute Type A Aortic Dissection. 61
33798045 2021
25
Radiation-induced lower-limb arteriopathy: report of 4 cases and systematic literature review. 61
33660497 2021
26
An oral absorbent, AST-120, restores vascular growth and blood flow in ischemic muscles in diabetic mice via modulation of macrophage transition. 61
33713645 2021
27
Early venoarterial extracorporeal membrane oxygenation improves outcomes in post-cardiotomy shock. 61
32926268 2021
28
Ultrafiltration and Injection of Islet Regenerative Stimuli Secreted by Pancreatic Mesenchymal Stromal Cells. 61
33403929 2021
29
Cardioprotection by remote ischemic conditioning is transferable by plasma and mediated by extracellular vesicles. 61
33689033 2021
30
Four-year outcomes following endovascular repair in patients with traumatic isolated popliteal artery injuries. 61
33340706 2021
31
Persistent sciatic artery in a patient with unilateral acute lower extremity ischemia. 61
33665539 2021
32
Computational fluid dynamics modeling aiding surgical planning in a toddler with Parkes Weber syndrome. 61
33747785 2021
33
Loss of endothelial glucocorticoid receptor promotes angiogenesis via upregulation of Wnt/β-catenin pathway. 61
33650028 2021
34
Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer. 61
33673912 2021
35
Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. 61
33753537 2021
36
The looming storm: Blood and cytokines in COVID-19. 61
32829962 2021
37
Six-month pivotal results of tack optimized balloon angioplasty using the Tack Endovascular System in below-the-knee arteries. 61
32956797 2021
38
Patent foramen oval: A rare case of acute ischemia of the upper limb: A case with 2 year follow-up. 61
33717477 2021
39
Total endovascular repair for a persistent sciatic artery aneurysm with widespread limb-threatening arterial occlusion. 61
33718683 2021
40
The impact of the COVID-19 pandemic on vascular surgery practice in the United States. 61
32889073 2021
41
Two-Year Outcomes of Endovascular Interventions of the Common Femoral Artery: A Retrospective Analysis From Two Medical Centers. 61
32921595 2021
42
Baseline and Updated Information on Nutritional Status in Patients With Chronic Limb Threatening Ischaemia Undergoing Revascularisation. 61
33358104 2021
43
A Retrospective Comparative Study of Twelve-Month Clinical Outcomes for Drug-Coating Balloon Angioplasty and Stent Implantation in Treating Patients with Popliteal Obstructive Lesions. 61
33249531 2021
44
The Effect of Preoperative Renal Failure on Outcomes Following Infrainguinal Endovascular Interventions for Peripheral Arterial Disease. 61
33386206 2021
45
pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcer: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial. 61
33726499 2021
46
Spinal cord stimulation in the treatment of peripheral vascular disease: a systematic review - revival of a promising therapeutic option? 61
33703962 2021
47
Alternative option for limb reperfusion cannula placement for percutaneous femoral veno-arterial ECMO. 61
33765883 2021
48
Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. 61
33772082 2021
49
A Pilot Study Investigating the Use of Regional Oxygen Saturation as a Predictor of Ischemic Wound Healing Outcome after Endovascular Treatment in Patients with Chronic Limb-Threatening Ischemia. 61
33786096 2021
50
Analyses of the pericyte transcriptome in ischemic skeletal muscles. 61
33726849 2021
Sources

Variations for Limb Ischemia

About this section
Sources

Expression for Limb Ischemia

About this section
Search GEO for disease gene expression data for Limb Ischemia.
Sources

Pathways for Limb Ischemia

About this section

Pathways related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.22 VWF VEGFA TNF TEK PGF NOS3
2
ERK Signaling 63
Show member pathways
 13.87 VEGFA TNF TEK PGF KDR IL6
3
GPCR Pathway 63
Show member pathways
 13.74 VEGFA TEK PGF NOS3 KDR IL6
4
PEDF Induced Signaling 63
Show member pathways
 13.71 TNF TEK NOS3 KDR IL6 HGF
5
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.59 TEK PGF NOS3 KDR IL6 HGF
6
TGF-Beta Pathway 63
Show member pathways
 13.54 VEGFA TNF TEK PGF KDR IL6
7
Akt Signaling 63
Show member pathways
 13.45 TNF TEK PGF NOS3 KDR IL6
8
Cytokine Signaling in Immune system 65
Show member pathways
 13.41 VWF VEGFA TNF TEK IL6 HIF1A
9
PAK Pathway 63
Show member pathways
 13.36 TNF TEK PGF KDR IL6 HGF
10
CREB Pathway 63
Show member pathways
 13.35 TEK PGF KDR IL6 HGF FGF2
11
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.35 VWF VEGFA TEK SELE NOS3 HGF
12
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.32 VEGFA TNF TEK PGF NOS3 KDR
13
Phospholipase-C Pathway 63
Show member pathways
 13.1 PGF KDR IL6 HGF FGF2 CXCL12
14
Human cytomegalovirus infection 36
Show member pathways
 13.01 VEGFA TNF IL6 HIF1A FGF2 CXCL12
15
p70S6K Signaling 63
Show member pathways
 12.95 PGF KDR IL6 HIF1A HGF FGF2
16
Pathways in cancer 36
12.91 VEGFA PGF IL6 HIF1A HGF FGF2
17
Ras signaling pathway 36
Show member pathways
 12.82 VEGFA TEK PGF KDR HGF FGF2
18
MAPK signaling pathway 36 1
12.82 VEGFA TNF TEK PGF KDR HGF
19
NF-KappaB Family Pathway 63
Show member pathways
 12.78 TNF PGF KDR IL6 HGF FGF2
20
PI3K-Akt signaling pathway 36
Show member pathways
 12.73 VWF VEGFA TNF TEK PGF NOS3
21
Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling Pathways 64
Show member pathways
 12.7 VEGFA NOS3 KDR CXCL12 CCL2
22
ErbB signaling pathway 36 1
Show member pathways
 12.69 VEGFA KDR IL6 HIF1A HGF FGF2
23
Immune response IL-23 signaling pathway 23
Show member pathways
 12.57 TNF TEK NOS3 IL6 FGF2 F2
24
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.47 TEK PGF KDR IL6 HGF FGF2
25
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.45 VEGFA SELE NOS3 KDR CCL2
26
Calcium signaling pathway 36
12.44 VEGFA NOS3 KDR HGF FGF2
27
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.36 TNF IL6 CXCL12 CCL2
28
Folate Metabolism 1
Show member pathways
 12.36 TNF IL6 F2 CCL2
29
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.35 TNF PGF KDR IL6 HGF FGF2
30
Proteoglycans in cancer 36
12.33 VEGFA TNF MIR21 KDR HIF1A HGF
31
Cell surface interactions at the vascular wall 65
Show member pathways
 12.27 TEK SELE F2 ANGPT2
32
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.21 VEGFA TNF IL6 HIF1A
33
Tyrosine Kinases / Adaptors 4
12.16 TEK KDR FGF2 ANGPT2
34
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.16 VEGFA KDR IL6 HGF FGF2
35
Fluid shear stress and atherosclerosis 36
12.16 VEGFA TNF SELE NOS3 KDR CCL2
36
TNF signaling pathway 36
12.03 TNF SELE IL6 CCL2
37
HIF-1 signaling pathway 36
12.01 VEGFA TEK NOS3 IL6 HIF1A ANGPT2
38
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.97 VEGFA PGF NOS3 KDR HIF1A
39
AGE-RAGE signaling pathway in diabetic complications 36
11.93 VEGFA TNF SELE NOS3 IL6 CCL2
40
Interleukin-4 and 13 signaling 65
11.86 VEGFA TNF IL6 HIF1A HGF FGF2
41
Rheumatoid arthritis 36
11.85 VEGFA TNF TEK IL6 CXCL12 CCL2
42
G-protein signaling_RhoA regulation pathway 23
11.78 PGF IL6 HGF FGF2 CXCL12
43
Lung fibrosis 1
11.76 TNF IL6 HGF FGF2 CCL2
44
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.75 VEGFA TNF SELE IL6
45
HIF-1-alpha transcription factor network 1
11.71 VEGFA HIF1A CXCL12
46
HIF1Alpha Pathway 63
11.63 VEGFA NOS3 HIF1A
47
Differentiation Pathway 1
11.62 VEGFA IL6 HGF FGF2
48
Malaria 36
11.61 TNF SELE IL6 HGF CCL2
49
Hepatitis C and Hepatocellular Carcinoma 1
11.6 VEGFA IL6 HIF1A
50
Interleukin-10 signaling 65
11.57 TNF IL6 CCL2
Sources

GO Terms for Limb Ischemia

About this section

Cellular components related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 VWF VEGFA TNF TEK PGF KDR
2 extracellular space GO:0005615 9.47 VWF VEGFA TNF SELE PGF MIR21
3 platelet alpha granule lumen GO:0031093 9.33 VWF VEGFA HGF

Biological processes related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 VEGFA TEK PGF IL6 HIF1A FGF2
2 multicellular organism development GO:0007275 10.25 VEGFA TNF TEK PGF KDR FGF2
3 negative regulation of apoptotic process GO:0043066 10.14 VEGFA TEK MIR21 KDR IL6 HIF1A
4 positive regulation of gene expression GO:0010628 10.12 VEGFA TNF NOS3 MIR21 IL6 HIF1A
5 positive regulation of cell proliferation GO:0008284 10.11 VEGFA PGF MIR21 KDR IL6 FGF2
6 MAPK cascade GO:0000165 10.05 TNF TEK HGF FGF2 CCL2
7 positive regulation of cell migration GO:0030335 10.05 VEGFA MIR21 KDR HGF CXCL12
8 leukocyte migration GO:0050900 10.02 TNF TEK SELE F2 ANGPT2
9 negative regulation of gene expression GO:0010629 10.02 VEGFA TNF MIR21 KDR HIF1A FGF2
10 cellular response to lipopolysaccharide GO:0071222 10.01 TNF MIR21 IL6 CCL2
11 positive regulation of protein kinase B signaling GO:0051897 10 VEGFA TNF TEK MIR21 HGF FGF2
12 regulation of cell shape GO:0008360 9.98 VEGFA MIR21 KDR F2 CCL2
13 cytokine-mediated signaling pathway GO:0019221 9.98 VEGFA TNF IL6 HIF1A HGF FGF2
14 negative regulation of angiogenesis GO:0016525 9.97 TEK MIR503 MIR21 ANGPT2
15 response to hypoxia GO:0001666 9.97 VEGFA TEK PGF HIF1A CXCL12 ANGPT2
16 positive regulation of MAPK cascade GO:0043410 9.95 VEGFA TEK KDR IL6 FGF2
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 VEGFA TNF IL6
18 angiogenesis GO:0001525 9.92 VEGFA TEK PGF KDR HIF1A FGF2
19 positive regulation of osteoblast differentiation GO:0045669 9.91 MIR21 IL6 HGF
20 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.91 VEGFA TNF HGF
21 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.91 VEGFA PGF KDR
22 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 VEGFA TNF TEK MIR21 KDR FGF2
23 positive regulation of MAP kinase activity GO:0043406 9.9 VEGFA TNF FGF2
24 humoral immune response GO:0006959 9.9 TNF IL6 CCL2
25 positive regulation of cell adhesion GO:0045785 9.89 VEGFA TNF CXCL12
26 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.89 TNF MIR21 FGF2
27 positive regulation of cell division GO:0051781 9.88 VEGFA PGF FGF2
28 animal organ regeneration GO:0031100 9.88 HGF CXCL12 ANGPT2
29 cellular response to virus GO:0098586 9.87 MIR21 IL6 HIF1A
30 positive chemotaxis GO:0050918 9.87 VEGFA PGF HGF FGF2
31 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.86 TNF HIF1A FGF2
32 negative regulation of endothelial cell proliferation GO:0001937 9.86 TNF MIR503 MIR21
33 negative regulation of blood vessel endothelial cell migration GO:0043537 9.86 TNF MIR503 FGF2 ANGPT2
34 protein kinase B signaling GO:0043491 9.85 TNF KDR CCL2
35 positive regulation of chemokine production GO:0032722 9.85 TNF IL6 HIF1A
36 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.85 VEGFA KDR FGF2
37 positive regulation of endothelial cell migration GO:0010595 9.85 VEGFA TEK MIR21 KDR FGF2
38 positive regulation of JAK-STAT cascade GO:0046427 9.84 TNF IL6 F2
39 sprouting angiogenesis GO:0002040 9.83 VEGFA TEK PGF
40 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.82 TNF MIR21 IL6
41 positive regulation of focal adhesion assembly GO:0051894 9.81 VEGFA TEK KDR
42 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.81 VEGFA MIR503 MIR21
43 positive regulation of protein phosphorylation GO:0001934 9.81 VEGFA TNF TEK PGF MIR21 KDR
44 cell migration involved in sprouting angiogenesis GO:0002042 9.8 VEGFA KDR FGF2
45 positive regulation of blood vessel endothelial cell migration GO:0043536 9.8 VEGFA NOS3 KDR HIF1A FGF2
46 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFA TEK PGF KDR HIF1A FGF2
47 vascular endothelial growth factor signaling pathway GO:0038084 9.79 VEGFA PGF KDR
48 positive regulation of DNA biosynthetic process GO:2000573 9.79 VEGFA HGF FGF2
49 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.78 TNF MIR21 IL6
50 induction of positive chemotaxis GO:0050930 9.77 VEGFA PGF CXCL12

Molecular functions related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.63 VEGFA TNF IL6 FGF2 CXCL12 CCL2
2 heparin binding GO:0008201 9.62 VEGFA PGF FGF2 F2
3 integrin binding GO:0005178 9.56 VWF KDR FGF2 CXCL12
4 vascular endothelial growth factor receptor binding GO:0005172 9.37 VEGFA PGF
5 chemoattractant activity GO:0042056 9.26 VEGFA PGF HGF FGF2
6 growth factor activity GO:0008083 9.17 VEGFA PGF IL6 HGF FGF2 F2
Sources

Sources for Limb Ischemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....